Retatrutide vs Tirzepatide: How the Triple Agonist Compares

How Each Drug Works at the Receptor Level

Tirzepatide is a dual agonist that activates GLP-1 and GIP receptors. Its structure is weighted toward GIP, with potency comparable to native GIP but reduced GLP-1 receptor activity relative to native GLP-1. This imbalance appears intentional: cryo-EM studies show that tirzepatide engages the GLP-1 receptor differently than native GLP-1, resulting in less receptor desensitization over time. Both receptor pathways suppress appetite, slow gastric emptying, and enhance insulin secretion.

Retatrutide adds a third target. It is a single peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Like tirzepatide, it has high GIP potency but lower GLP-1 potency relative to native hormones. The distinguishing feature is glucagon receptor activation, which increases energy expenditure and fatty acid oxidation. A phase 1b trial confirmed that retatrutide also delays gastric emptying, contributing to reduced food intake and lower post-meal glucose.

Weight Loss: What the Clinical Trials Show

In a phase 2 trial of 338 adults with obesity but without diabetes, retatrutide 12 mg produced a mean weight loss of 24.2% at 48 weeks. The 8 mg dose achieved 22.8%. A network meta-analysis of 27 randomized controlled trials (15,584 patients) ranked retatrutide 12 mg as the most effective treatment, with a placebo-adjusted weight reduction of 22.1%. Retatrutide 8 mg came second at 20.7%.

Tirzepatide 15 mg ranked third in the same analysis, with 16.5% weight loss from baseline. A model-based meta-analysis of 55 studies (16,269 participants) estimated maximum weight reduction of 22.6 kg for retatrutide compared to a modeled range of 11 to 23% for tirzepatide depending on dose and population. In people with type 2 diabetes, both drugs produce less weight loss than in non-diabetic populations. Zepbound (tirzepatide 15 mg) remains the most effective FDA-approved option for weight management.

Blood Sugar and Glycemic Control

In a phase 2 trial of 281 people with type 2 diabetes, retatrutide reduced HbA1c by up to 2.2%, with 82% of participants in the 12 mg group reaching HbA1c of 6.5% or below at 36 weeks. A Bayesian network meta-analysis of dual and triple incretin agonists found that tirzepatide was the most effective for lowering fasting blood glucose (mean difference of -57.3 mg/dL vs. placebo) and HbA1c (-1.88% vs. placebo).

The pattern across multiple meta-analyses is consistent: retatrutide tends to produce greater weight loss, while tirzepatide has a slight edge in glycemic control. This may reflect tirzepatide's GIP-weighted design, which enhances glucose-dependent insulin secretion. For patients with type 2 diabetes specifically, both drugs reduce HbA1c by more than 1%, putting them in a class above older GLP-1 receptor agonists like liraglutide.

Liver Fat Reduction

Retatrutide shows a particularly strong signal for liver fat. In a randomized phase 2a substudy of 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks. The 8 mg dose achieved 81.4%. Normal liver fat levels (below 5%) were reached by 86% of participants on 12 mg and 79% on 8 mg, compared with 0% on placebo.

This degree of liver fat clearance exceeds what has been reported for tirzepatide and other GLP-1 agonists at comparable weight loss levels. Researchers attribute the difference to glucagon receptor activation, which directly promotes hepatic fatty acid oxidation independently of weight loss. For people with fatty liver disease, this added mechanism is a meaningful distinction between the two drugs.

Blood Pressure and Cardiovascular Markers

A systematic review and network meta-analysis of blood pressure effects across GLP-1 receptor agonist classes found that retatrutide produced the largest systolic blood pressure reduction, approximately 7 mmHg. Tirzepatide lowered systolic blood pressure by about 5.2 mmHg and diastolic by 1.7 mmHg. Both drugs improved waist circumference and lipid profiles in their respective trials.

A separate meta-analysis of 24 trials (9,165 participants) confirmed that tirzepatide significantly reduces systolic blood pressure (-6.7 mmHg) and diastolic blood pressure (-3.7 mmHg). Retatrutide also improved multiple cardiometabolic parameters in its phase 2 program, including waist circumference and lipid levels. Phase 3 cardiovascular outcome trials for retatrutide are ongoing but not yet reported.

Side Effects and Tolerability

Both drugs share a common side effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation. These effects are dose-related and most frequent during early dose escalation. A Bayesian network meta-analysis of 19 trials (29,506 adults) found that retatrutide had the highest overall adverse event risk among all GLP-1 receptor agonists and polyagonists evaluated.

Tirzepatide also increases adverse events compared to placebo, but network analyses consistently show it has a more favorable tolerability profile than retatrutide. A network meta-analysis of 27 trials found no significant difference in serious adverse events or treatment discontinuation rates between any of the drugs in head-to-head comparisons. Cholelithiasis (gallstones) has been flagged as a potential concern with retatrutide, though serious events remain rare across both drugs.

Regulatory Status and What Is Available Now

Tirzepatide is FDA-approved under two brand names: Zepbound for chronic weight management and Mounjaro for type 2 diabetes. It has completed phase 3 trials and has published data on cardiovascular outcomes, long-term safety, and efficacy across multiple populations. It is available by prescription in the United States.

Retatrutide is currently in phase 3 trials under the TRIUMPH program, which is evaluating efficacy, safety, and cardiovascular and renal outcomes in people with obesity and type 2 diabetes. No regulatory agency has approved retatrutide for any indication. All published efficacy and safety data come from phase 1 and phase 2 studies, which involve smaller populations and shorter durations than the trials required for approval.

The Bottom Line for People Considering Treatment

Retatrutide's early data is striking. Phase 2 results suggest it may ultimately produce greater weight loss than any currently approved drug, with particularly notable effects on liver fat. But the operative word is "may." No phase 3 results have been published, no head-to-head trial against tirzepatide exists, and the safety profile needs larger and longer studies to characterize fully.

For people looking for treatment now, Zepbound (tirzepatide) offers the strongest combination of weight loss, glycemic improvement, and established safety data among approved medications. It produces 15 to 17% weight loss in clinical trials, is backed by large phase 3 programs, and has a more favorable tolerability profile than retatrutide in indirect comparisons. If retatrutide's phase 3 results confirm what phase 2 showed, it could become an important option in the future, particularly for patients with fatty liver disease.